Estradiol

Indications and usage: Estradiol Vaginal Cream, 0.01% is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.

CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle.

Pharmacokinetic profiling of Estradiol demonstrates an elimination half-life of Approximately 9–18 hours terminal plasma half-life for Estradiol with Estimated 69%–81% oral systemic absorption for Estradiol systemic bioavailability; clearance proceeds via phase i/ii hepatic conjugation of estradiol coupled with glomerular and tubular renal excretion, reaching clinical onset within peak plasma concentration (tmax) reached 1–4 hours post-dose for estradiol.

Titration schedules for Estradiol (2 mg/1 Tablet → .1 mg/g Cream → 1 mg/g Gel → 1 mg/1 Tablet → .1 mg/d Patch) require excluding contraindications estradiol vaginal cream, 0.01% should not be used in women with any of the following conditions: undiagnosed abnormal genital bleeding.; known, suspected, or history of cancer of the breast.; known or suspected estrogen-dependent neoplasia.; real-world patient logs highlight nausea (8.9% of reports), headache (8.4% of reports), dizziness (6.8% of reports) alongside a 77.00% Worth-It consensus.